Identification of Risk Factors Parkinson's Disease by Convergence Strategy (CONVERGENCE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03536104|
Recruitment Status : Recruiting
First Posted : May 24, 2018
Last Update Posted : August 25, 2020
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||2220 participants|
|Official Title:||Identification of Risk Factors Parkinson's Disease by Convergence Strategy|
|Actual Study Start Date :||March 25, 2009|
|Estimated Primary Completion Date :||March 2024|
|Estimated Study Completion Date :||March 2024|
This group will include "healthy" person.
This group will include Parkinsonian patients
patients with a related disease.
This group will include patients with a related disease.
- Significant variations in the frequencies of gene polymorphisms and the risk of developing Parkinson's disease [ Time Frame: through study completion, an average of 10 years ]the frequency is measured according to biological and environmental variables modulating the risk of developing Parkinson's disease.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03536104
|Contact: Alain DESTEE, MD,PhDemail@example.com|
|Hôpital Roger Salengro, CHRU de Lille||Recruiting|
|Principal Investigator: Alain DESTEE, MD,PhD|
|Principal Investigator:||Alain DESTEE, MD, PhD||University Hospital, Lille|